1. Shedding Light on HDL: Myths and Controversies

2. Panelists

3. The HDL Hypothesis

4. Residual Clinical Risk in Statin Trials

5. TNT: On-Treatment HDL-C Predicts CV Event 5-Year Risk When LDL-C Is < 70 mg/dL

6. Infusing HDL Slows Development and Promotes Regression of Atherosclerosis

8. AIM-HIGH: Study Design

9. AIM-HIGH: HDL-C After 36 Months of Follow-up

10. Current Pharmacologic Approaches to Raising HDL-C

11. SATURN: Change in LDL-C and HDL-C From Baseline

13. Evidence From Prior Placebo-Controlled Trials Supporting Niacin Benefit

14. CETP Inhibitors: Past and Present

15. CETP Deficiency

16. CETP Deficiency: Genotype and CAD Risk

18. ILLUMINATE: Protocol-Specified Outcomes

19. DEFINE: BP Results at 18 Months

21. Evacetrapib: BP Results

22. Comparison of CETP Inhibitors

23. DEFINE: Effect of Anacetrapib on Lp(a)

24. Ongoing CETP Outcomes Trials

25. Program Summary